AzTrials
AzTrials

MalariaDRIPICCONCT01936766

Optimal Fluid Management in Adult Severe Malaria

An observational study of Malaria and Sepsis, run by University of Oxford at 1 site in Bangladesh.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Optimal fluid therapy in severe falciparum malaria has not been well defined, especially in resource poor settings where access to mechanical ventilation is limited. Recent studies suggest that liberal fluid resuscitation is harmful for severe malaria patients despite they often being hypovolemic on admission. Read more about this study

Who is it for?
Ages 16 to 65 years
Conditions the study is for
Malaria, Sepsis
How many people
156 participants
Where
1 siteBangladesh
Study dates
May 2013to Dec 2017
How long will I take part?
14 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 65 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients with severe malaria or severe sepsis admitted to the secondary or tertiary care center

Who may be able to join

  • Severe Malaria
  • Any level of asexual form of P. falciparum parasitemia on blood smear
  • Severe malaria with one or more of the following:
  • Cerebral malaria (GCS < 11). ii. Renal impairment (Creatinine > 2mg/dL or Anuria) iii. Hypoglycaemia (Glucose < 40mg/dL) iv. Systolic blood pressure < 80mmHg with cool extremities v. Pulmonary edema vi. Venous bicarbonate < 15mmol/L vii. Venous lactate > 4mmol/L
  • Age 16-65 years
  • Written informed consent obtained from patient or attending relative.
Show all 14Show fewer
  • Severe Sepsis
  • Negative blood smear for any Plasmodium species
  • Clinical signs of infection with two of following:
  • Heart rate > 90/min ii. Respiratory rate > 20/min iii. Body temperature >38°C or <36°C iv. White blood cell count of > 12000/μL or < 4000/μL
  • Severe sepsis with one or more of the following due to infection:
  • Systolic blood pressure < 90mmHg despite fluid resuscitation ii. Lactate > 4mmol/L iii. Urine output < 0.5mL/kg/hour for > 2 hours despite fluid resuscitation iv. Acute lung injury with PaO2/FiO2 < 250 in the absence of pneumonia v. Acute lung injury with PaO2/FiO2 < 200 in the presence of pneumonia vi. Creatinine > 2mg/dL vii. Bilirubin > 2mg/dL viii. Platelet count < 100000/μL
  • Age 16-65 years
  • Written informed consent obtained from patient or attending relative

Who cannot join

  • Severe Malaria
  • Patient or relative unable or unwilling to give informed consent
  • Serious pre-existing disease The following exclusion criteria described below are applied to patient for whom invasive hemodynamic monitoring will be performed.
  • Spontaneous bleeding or platelet count < 30000/μL on enrollment
  • Pregnancy.
  • Contraindication or unsuitable condition for thermodilution technique
Show all 12Show fewer
  • Severe Sepsis
  • Patient or relative unable or unwilling to give informed consent
  • Serious pre-existing disease The following exclusion criteria described below are applied to patient for whom invasive hemodynamic monitoring will be performed.
  • Spontaneous bleeding or platelet count < 30000/μL on enrollment
  • Pregnancy.
  • Contraindication or unsuitable condition for thermodilution technique

Trial locations and contacts

1 site in 1 country.

Bangladesh1 site
  • Chittagong Medical College Hosiptal

    Chittagong

Other trials in Bangladesh

About this study

Official title: Optimal Fluid Management in Adult Severe Malaria - Development of Renal Impairment and Pulmonary Edema in Complicated Malaria Under Conventional Fluid Strategy

Optimal fluid therapy in severe falciparum malaria has not been well defined, especially in resource poor settings where access to mechanical ventilation is limited. Recent studies suggest that liberal fluid resuscitation is harmful for severe malaria patients despite they often being hypovolemic on admission. In order to elucidate the minimum fluid therapy required to prevent complications in severe malaria, we will conduct a prospective observational study in adults with severe malaria, and also in adults with severe sepsis as a comparison group. The objective of this study is to describe the association between hemodynamic variations in conventional fluid management and the probability of developing acute kidney injury (AKI) or pulmonary edema in adults with severe malaria and severe sepsis. Hemodynamic measurements will be obtained by using transpulmonary thermodilution and arterial pulse contour analysis.

Read the detailed description

Background

Fluid therapy in severe malaria and severe sepsis.

Severe falciparum malaria causes multiple organ dysfunction including metabolic acidosis, coma, anemia, acute kidney injury (AKI), and pulmonary edema. The mortality rate of the disease is still around 15-23% despite optimal antimalarial therapy. Supportive therapy and intensive care are crucial elements in the treatment of the multiple complications of the disease. Optimal fluid therapy however, one of the fundamental elements of the supportive therapy, has not been well defined. A large randomized controlled trial of fluid therapy in shocked African children (the FEAST study) showed that fluid bolus resuscitation increased the mortality in severe malaria. A retrospective study in adult patients with severe malaria showed that fluid loading had no effect on acid-base status or renal failure. A recent study by our group showed that liberal fluid management guided by invasive monitoring was not associated with improved renal function or acid-base status, but did aggravate pulmonary edema in patients developing pulmonary capillary leakage during admission in the intensive care unit. The study found that 38% of severe malaria patients developed clinical pulmonary edema, 80% of which occurred after liberal fluid resuscitation. In this study, plasma lactate as a crude measure of tissue hypoperfusion correlated with the degree of sequestration (directly observed by OPS imaging), and not with the volume of fluid resuscitation. It was concluded that liberal fluid management is not indicated in adult severe malaria. However, this same study showed that all patients with severe malaria present with intravascular dehydration, and often have not been able to maintain proper fluid intake for a considerable time. Failure to give these patients enough fluid therapy could therefore be expected to precipitate renal failure and tissue hypoperfusion. Overall, the evidence suggests that in severe malaria, liberal fluid resuscitation is harmful despite patients often being hypovolaemic on admission. The minimum fluid therapy required to prevent complications has yet to be defined. Currently, the clinician has no guidance except for the very general adage: "keep them dry".

Evidence for fluid therapy in sepsis and septic shock is also limited. Goal-directed resuscitation during the first 6 hours is recommended by the Surviving Sepsis Campaign Guideline (SSCG), based on two randomized controlled study. Fluid challenges are one of the methods used to achieve the goals, with administration of fluid boluses and initial higher volume of intravenous fluids. Due to its inclusion in guidelines1, early goal-directed therapy (EGDT) and fluid challenges have now become common clinical practice in resource-rich countries. On the other hand, the efficacy of large fluid bolus resuscitation is questioned because of low level of evidence for physiological support and lack of clinical controlled trials comparing fluid bolus therapy versus no fluid bolus therapy. The variable availability of mechanical ventilation must be considered when making recommendations for fluid resuscitation. Since access to mechanical ventilation is often limited in developing world settings, the recommendations in the SSCG are not applicable in this context without additional evaluation. Recently, the FEAST trial in East African children with compensated shock in severe malaria and sepsis revealed that fluid bolus therapy of 20 to 40 mL/kg body weight caused a dramatic increase in case fatality. Several studies have found positive fluid balance to be associated with increased mortality in sepsis or septic shock. A retrospective study (the VASST study) included 778 patients with septic shock showed that there is significant correlation between a more positive fluid balance at both time points of 12 hours and day 4 and increased mortality. In the SOAP study, multicenter prospective cohort study enrolled 1177 patients with sepsis, cumulative fluid balance within first 72 hours after the onset was an independent predictor of mortality. Also, a prospective observational study of 164 patients with septic shock reported that there was no significant difference in 90-days mortality between patients with higher fluid volume infused (> 4.0 L) and lower volume (< 4.0 L) on day 1. They concluded that initial fluid volume administered was not associated with mortality in patients with septic shock. Optimal initial fluid volume and strategy in sepsis and septic shock is thus unclear. Especially in resource-limited countries, fluid overload is more dangerous than that in resource-rich countries, because development of pulmonary edema and ALI/ARDS is almost always fatal in settings without access to mechanical ventilation. The recommendation of fluid bolus resuscitation therapy as promoted in the SSCG should therefore be evaluated cautiously in the resource-poor setting.

Rationale

As outlined above, the optimum fluid management in severe malaria and sepsis has yet to be established, particularly in resource poor settings where access to mechanical ventilation is limited. Whilst liberal fluid resuscitation appears deleterious, it is not clear what the minimum fluid requirements are; this study aims to address this question.

Procedures

The investigators will longitudinally monitor the hemodynamic parameters along with cumulative fluid administration and fluid balance during conventional fluid strategy, as practiced by the local physicians. For monitoring, we will use transpulmonary thermodilution and arterial pulse contour analysis (PiCCO-plus, Pulsion Medical System, Germany). The PiCCO system is in routine use as part of standard clinical practice to provide hemodynamic monitoring of severely ill patients admitted to ICU. It uses a central venous and arterial line to provide continuous monitoring of hemodynamic function.

Overall, the investigators believe that by monitoring the hemodynamics using the PiCCO system will give valuable new insight into the relationship between fluid management and renal function, pulmonary edema, and acid-base status in adult patients with severe malaria. Patients with severe sepsis will be recruited as a comparison group, and the volume status will be evaluated in the same manner.

Conditions
Malaria, Sepsis
Keywords
malaria, falciparum, sepsis, fluid therapy, thermodilution, extravascular lung water, acute kidney injury
Medical subject headings
Malaria, Sepsis, Malaria, Falciparum, Acute Kidney Injury

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Association between the mean Global End-Diastolic Volume Index and serum creatine level and extravascular lung water index

    The association between the mean Global End-Diastolic Volume Index (GEDVI) over the first 24 hours and (1) serum creatinine level, and (2) Extravascular Lung Water Index (EVLWI)

    Measured: 24 hours

Secondary outcomes (11)
  1. Association between the GEDVI,after conventional fluid resuscitation, and (1) serum creatinine level, (2) EVLWI

    The association between the GEDVI at 6, 12, 18 or 24 hours after conventional fluid resuscitation and (1) serum creatinine level, (2) EVLWI

    Measured: 24 hours

  2. Correlation between GEDVI and changes over time in plasma lactate level

    Measured: 72 hours

  3. Change in central venous oxygen saturation (ScvO2) in relation to GEDVI and its association with acid-base status

    Measured: 72 hours

  4. Incidence of pulmonary edema and ALI/ARDS

    Incidence of pulmonary edema defined by increase of EVLWI (≥ 10 mL/kg) and ALI/ARDS in relation to proportion of blocked capillaries (observed by OPS), GEDVI and cumulative fluid administration

    Measured: 72 hours

  5. Incidence of AKI and induction rate of renal replacement therapy

    Incidence of AKI defined by RIFLE or AKIN criteria and induction rate of renal replacement therapy in relation to proportion of blocked capillaries (observed by OPS), GEDVI and cumulative fluid balance

    Measured: 72 hours

  6. Time course of hemodynamic parameters in relation to fluid therapy

    Time course of hemodynamic parameters, i.e. Cardiac Index (CI), Global Ejection Fraction (GEF), Stroke Volume Variation (SVV) in relation to fluid therapy

    Measured: 72 hours

  7. Time course of respiratory parameters in relation to fluid therapy

    Time course of respiratory parameters, i.e. PaO2/FiO2 ratio, Pulmonary Vascular Permeability Index (PVPI) in relation to fluid therapy

    Measured: 72 hours

  8. Parasite burden in adults with severe malaria in relation to organ damage (renal, pulmonary)

    Parasite burden, i.e. PfHRP2, peripheral blood parasitemia, parasite staging at enrollment in adults with severe malaria in relation to organ damage (renal, pulmonary)

    Measured: 72 hours

  9. Evaluation of Biomarkers for early detection of ARDS

    Evaluation of Biomarkers for early detection of ARDS in both severe malaria and sepsis (plasma transferrin, albumin, others)

    Measured: 72 hours

  10. Correlation between GEDVI and clinical variables

    Correlation between GEDVI and clinical variables including the jugular venous pressure (JVP) as a measure of volume status or passive leg raising as an indicator of fluid responsiveness

    Measured: 72 hours

  11. Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis

    Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis, based on the optimal GEDVI defined by primary outcome measures and secondary outcome measures No. 1

    Measured: 72 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Sep 2013 (estimated)
  2. Study startMay 2013
  3. Primary completionDec 2017
  4. Study completionDec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
156 participants (actual)
Target duration
14 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT01936766
Sponsor's protocol ID
BAKMAL 1302
Acronym
DRIPICCO
Status last verified
Aug 2018
First submitted
27 Aug 2013
Last updated
16 Aug 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Malaria and Sepsis, run by University of Oxford at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Association between the mean Global End-Diastolic Volume Index and serum creatine level and extravascular lung water index (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in